Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Summary

HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20 insertion mutation. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10376 in Chinese advanced Non-Small Cell Lung Cancer (NSCLC) patients.

Timeline

Start

2021-09-30

Primary completion

2024-10-07

Completion

2025-10-07

Drugs

Indications